Tag Archives: Cholesterol

Kellogg’s Optivita and H·E·A·R·T UK, the cholesterol charity, have teamed up to work together on a programme of joint actions. This will include educational initiatives to support healthcare professionals, particularly practice nurses and dietitians who see people everyday at risk of heart disease due to factors such as high cholesterol, and the provision of practical advice for consumers to help them lower their cholesterol. Optivita has been specifically developed with oat beta-glucan, which has been shown in many studies to help to lower cholesterol.

Cholesterol and cardiovascular disease Cholesterol has the Jekyll and Hyde characteristics of being both essential to life as a constituent of the body’s cells and of being the prime initiator of atherosclerosis, a process characterised by the formation of cholesterol-rich plaques in arteries. This disorder is the major cause of cardiovascular disease, mainly coronary heart disease and stroke, from which 11 million people die in the world each year. The most common single cause of death in Britain, its eradication is given a high priority by the government. Numerous studies have identified cholesterol, specifically low-density lipoprotein (

(more…)

Introduction Coronary heart disease (CHD) is responsible for over 100,000 deaths annually in the UK.1 Epidemiology studies have long supported that cholesterol is a key risk factor for cardiovascular disease (CVD).2 In both primary and secondary prevention, statin therapy trials have shown that there is a clear relationship between lowering cholesterol and reducing cardiovascular risk in both primary and secondary prevention.3 However, The World Health Report 2002 estimates that over 50% of CHD globally is still due to elevated blood cholesterol levels.4 Table 1. Recommended targets for total cholesterol (TC) and low-density lipoprotein chol

The product is a polymer in tablet form that lowers LDL-cholesterol.  It can be taken as adjunctive therapy to diet, in combination with other cholesterol-lowering medications, such as statins, or alone, when statins are inappropriate or not well-tolerated. When combined with statins, colesevelam hydrochloride has been shown to have an additive LDL-cholesterol lowering effect in the range of 8–16%.

A total of 2,511 switch patients and 9,009 controls were identified. The risk of death or first major cardiovascular event was significantly associated with switching therapy (hazard ratio = 1.30, 95% confidence interval: 1.02–1.64) compared with patients who did not switch. Major cardiovascular events and stroke were also significantly associated with switching. There was no significant difference in all-cause mortality.  While recognising the observational nature of database research, this study has highlighted the potential for poorer cardiovascular outcomes in patients switching statin therapy, compared with patients maintained on thei

No content available

No content available

No content available

No content available